AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Aug 28 2018 AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th
- Aug 1 2018 AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)
- Jun 29 2018 AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
- May 30 2018 AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer